These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36513818)

  • 61. Prognostic significance of clinical characteristics and
    Liu Y; Jiang J; Liu L; Wang Z; Yu B; Xia Z; Zhang Q; Ji D; Liu X; Lv F; Hong X; Song S; Cao J
    J Int Med Res; 2022 Jan; 50(1):3000605211063027. PubMed ID: 35001690
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Predictive Significance of a New Prognostic Score for Patients With Diffuse Large B-Cell Lymphoma in the Interim-Positron Emission Tomography Findings.
    Kong Y; Qu L; Li Y; Liu D; Lv X; Han J
    Medicine (Baltimore); 2016 Feb; 95(6):e2808. PubMed ID: 26871850
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
    Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Prognostic value of international prognostic index, revised international prognostic index, enhanced international prognostic index and Grupo Español de Linfomas/trasplante autólogo de médula ósea-international prognostic index for diffuse large B-cell lymphoma].
    Feng YX; Su LP
    Zhonghua Zhong Liu Za Zhi; 2020 Nov; 42(11):949-954. PubMed ID: 33256307
    [No Abstract]   [Full Text] [Related]  

  • 65. The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas.
    Prieto Prieto JC; Vallejo Casas JA; Hatzimichael E; Fotopoulos A; Kiortsis DN; Sioka C
    Ann Nucl Med; 2020 Oct; 34(10):707-717. PubMed ID: 32924071
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The prognostic value of splenic abnormalities in pretreatment
    Wang S; Ju H; Bai Y; Wang L; Ding Q; Li P; Jiang X; Lin X
    Clin Radiol; 2023 May; 78(5):375-380. PubMed ID: 36805286
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients.
    Qu C; Zou R; Wang P; Zhu Q; Kang L; Ping N; Xia F; Liu H; Kong D; Yu L; Wu D; Jin Z
    Front Immunol; 2022; 13():969660. PubMed ID: 36059523
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparison of the prognostic values of
    Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
    Sci Rep; 2020 Jul; 10(1):12748. PubMed ID: 32728134
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 70. Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.
    Husby T; Johansen H; Bogsrud TV; Hustad KV; Evensen BV; Boellaard R; Giskeødegård GF; Fagerli UM; Eikenes L
    BMC Cancer; 2022 Nov; 22(1):1117. PubMed ID: 36319985
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells.
    Galtier J; Vercellino L; Chartier L; Olivier P; Tabouret-Viaud C; Mesguich C; Di Blasi R; Durand A; Raffy L; Gros FX; Madelaine I; Meignin V; Mebarki M; Rubio MT; Feugier P; Casasnovas O; Meignan M; Thieblemont C
    Haematologica; 2023 Jan; 108(1):171-180. PubMed ID: 35678029
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
    Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
    BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
    Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
    Wang J; Hu Y; Yang S; Wei G; Zhao X; Wu W; Zhang Y; Zhang Y; Chen D; Wu Z; Xiao L; Chang AH; Huang H; Zhao K
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1092-1098. PubMed ID: 30769193
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prediction of Overall Survival and Progression-Free Survival by the
    Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
    Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
    [No Abstract]   [Full Text] [Related]  

  • 77. Baseline
    Aide N; Fruchart C; Nganoa C; Gac AC; Lasnon C
    Eur Radiol; 2020 Aug; 30(8):4623-4632. PubMed ID: 32248365
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic Impact of Pretreatment 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
    [No Abstract]   [Full Text] [Related]  

  • 79. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
    Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
    Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prognostic significance of bone marrow 2-[
    Lim CH; Hyun SH; Cho YS; Choi JY; Lee KH
    Clin Radiol; 2021 Jul; 76(7):550.e19-550.e28. PubMed ID: 33762136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.